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Abstract: Nucleic acids are able to adopt a plethora of structures, many of which are of 
interest in therapeutics, bio- or nanotechnology. However, structural and biochemical 
stability is a major concern which has been addressed by incorporating a range of 
modifications and nucleoside derivatives. This review summarizes the use of locked 
nucleic acid (LNA) and un-locked nucleic acid (UNA) monomers in functional nucleic 
acids such as aptamers, ribozymes, and DNAzymes. 




Ribozymes, DNAzymes, and aptamers, collectively referred to as ‘functional nucleic acids’, are 
RNA or DNA structures with sequence-specific folds. These functional nucleic acids achieve their 
tertiary folds and activity through a combination of different molecular interactions and motifs: 
Hydrogen bonds, hydrophobic interactions, van der Waals forces, canonical and non-canonical base 
pairs, base stacking, coaxial stacking, tetraloops, G-quadruplexes, and metal ion coordination [1,2]. 
However, the use of nucleic acids in therapeutics and bio- and nanotechnologies is troubled by 
denaturation and/or biodegradation of the nucleic compounds. Non-natural nucleosides may offer 
improved half-life in vivo, better structural stability, or novel interacting groups. 2’-modified 
ribonucleoside analogues have attracted interest, as modification to this position on the ribose often 
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explain these results. Santaris Pharma A/S currently has LNA-based drugs against e.g., hepatitis C or 
tumor growth, in clinical trials [44,45]. 
One of the motivations for employing LNA is its stability towards nucleases. Short interfering 
RNAs (siRNA) are rapidly degraded by blood ribonucleases, but introduction of two LNA moieties at 
both 3’ termini has been shown to offer protection in human serum beyond 6 hours, a 4-fold 
improvement over the unmodified siRNA. Replacing one strand with a DNA/LNA mix-mer further 
improved stability beyond 48 h. Similar results were obtained in 10% foetal bovine serum and 100% 
mouse serum [46], as well as in live mouse blood [47] and with similar oligo designs [48]. 
Deoxyribonuclease activity in blood is generally believed to be shared among deoxyribonuclease I 
(DNase I), DNase II, and phosphodiesterase I with the former being the main component. Two or more 
LNA moieties towards the 3’ end can offer efficient protection against snake venom phosphodiesterase 
I (SVPD) [49]. SVPD is, however, able to completely digest substrates of a scattered arrangement with 
singular LNAs [50,51]. DNase I is an endonuclease that cleaves single- or double-stranded DNA 
adjacent to pyrimidines. Remarkably, by using 5’ and 3’ terminal LNA nucleosides together on both 
strands in a DNA duplex Crinelli et al. [52] saw a marked improvement in stability over that observed 
with the unmodified DNA duplex. Internal modifications did not improve the nuclease resistance further, 
though. In human serum the increase on DNA oligomer half-life varies with the number of terminal 
LNA moieties, from 2.5-fold (1 LNA at either end), 11-fold (3 LNA monomers at both ends) to 15-fold 
(4 LNA monomers at either end) [14]. Further gains can be achieved with mix-mer designs, which have 
been shown to yield 30-fold improvements in half-life [38]. Together, these reports leave little doubt that 
modification with LNA offers tremendous advantages regarding stability of therapeutic oligomers. 
3. Functional Nucleic Acids with LNA 
3.1. LNA in Aptamers 
Aptamers are nucleic acid oligonucleotides, whose sequence allows them to fold into defined 
tertiary structures that act as ligands and bind their corresponding target molecule with specificity and 
affinity rivalling that of antibodies. Aptamers have been raised against metal ions, small organic dyes, 
neurotransmitters, nucleotides, cofactors, amino acids, oligonucleotides, carbohydrates, antibiotics, 
many proteins, anthrax spores, and live cells. A more comprehensive list is provided elsewhere [53]. 
The potential uses of aptamers are numerous and include applications in purification, sensors, 
diagnostics, and therapeutics. Further information can be found in excellent reviews, e.g., [54-56] and 
references highlighted therein. However, to date, only 14 aptamer-based drugs have entered clinical 
trials [55]. 
One the first reports of LNA modification to an RNA aptamer was that of the HIV-1 trans-activation 
responsive (TAR) RNA ‘aptamer’ R06 that disrupts the TAT-Tar interaction by forming a ‘kissing 
loop’ complex with the TAT RNA [57]. As its binding mode consists of base-pairing of  
six nucleotides in the apical loop to the TAR RNA it can be argued that this is not a true aptamer but a 
cross-over to the field of antisense oligomers. LNA modifications were placed within these  
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A similar study on an avidin-binding DNA aptamer was recently published by our lab. The 
previously un-optimized aptamer [71] was truncated from 61 to 21 nucleotides, increasing the Kd  
10-fold. The aptamer was then screened for various single and dual LNA substitutions, and one 
substitution restored the Kd to that of the original aptamer. 2’-O-methyl substitution at this site did not 
yield the same effect. Further introduction of T-2’-amino-LNA caused only a small increase in Kd, 
suggesting that this aptamer was very tolerant towards LNA modifications in general (Figure 2d) [63]. 
Shangguan et al. [64] truncated aptamer ‘sgc8’ against T-cell leukaemia cell line CCRF-CEM while 
retaining its Kd. Various LNA substitutions were tested and LNA was accepted in the terminal stem 
region. This modification, along with replacing a presumed single-stranded region with a polyethylene 
glycol linker, yielded an aptamer with markedly improved serum stability and a Kd ~2-fold higher than 
that of the original aptamer (Figure 2e). 
The most recent example of an LNA-modified aptamer is the modification of DNA aptamer 
‘TD05’, which binds a B-cell surface epitope dubbed ‘mIgM BCR’ that is expressed on B-cells and 
many B-cell lymphomas [72,73]. The aptamer’s stem-loop structure was truncated, causing a near  
10-fold increase in target affinity, and linking multiple aptamers together yielded up to 5-fold further 
improvements. Three arrangements of LNA were evaluated and LNA modification of pyrimidines at 
the base of the stem gave the best results and offered, as expected, prolonged stability in human serum 
(Figure 2f) [65]. 
3.2. LNA in Catalytic Nucleic Acids 
The term ‘ribozyme’ refers to well-defined RNA structures with the ability to catalyse specific 
chemical reactions. The first ribozyme to be discovered was a self-splicing RNA [74,75]. Since then, 
ribozymes have been identified in a number of various biological settings, as well as in in vitro 
experiments [76]. Deoxyribozymes or ‘DNAzymes’ are equivalent catalytic DNA structures obtained 
by in vitro selection, of which the first was an RNA-cleaving Pb2+-dependent DNA oligomer [77]. 
Although the tertiary interactions required for catalysis remain elusive modification with LNA has 
been investigated. 
Catalytic nucleic acids that cleave RNA bind their substrates by Watson-Crick base-pairing and 
thus seem very well suited to modification with LNA. For instance, the ‘10–23’ DNAzyme [78] was 
modified to contain two LNA monomers in each of the binding arms, which resulted in much 
improved cleavage of even a highly structured RNA of 2,904 nucleotides as well as the 17 nucleotide 
minimal RNA substrate [27,34]. Incorporation of 3–4 LNA moieties into another ‘10-23’ variant 
yielded similar results against viral RNA and even cleaved otherwise inaccessible targets in highly 
structured RNA but at the cost of decreased turnover rates [33,36]. A number of studies demonstrating 
similar modifications to the substrate binding arms have also been published [28-32,34,35,37]. 
Beneficial modification of the catalytic cores has proven more difficult. Robaldo et al. [79] 
introduced LNA-T into two positions in the ‘10–23’ core and this drastically reduced the activity of the 
enzyme (Figure 3a). The purported catalytic stem-loop of the ‘8–17’ DNAzyme [78] has been the 
target of LNA modification in our lab, but this led to inactivation of the modified DNAzyme [80]. 
Christiansen et al. [81] explored LNA incorporation into the ‘hammerhead’ ribozyme [82] and 
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potent UNA-modified siRNAs did not affect cell viability. Rigorous studies on toxicity have not yet 
been carried out, however. 
4.2. UNA in Aptamers 
So far, there is only a single published report on UNA-modification to an aptamer: the thrombin-
binding DNA aptamer, TBA [67] was systematically substituted with UNA-G or -U monomers. 
Substitution with UNA-U was tolerated at several positions, and modification to position 7 (Figure 2g) 
lead to a slightly improved Kd (from 103 nM to 78 nM) and a ~3-fold improvement in antithrombin 
effect, as judged by a fibrin-clot formation assay [66]. The DNA aptamer adopts a G-quadruplex 
structure, and this places the UNA-U monomer in the central loop. However, structural data on the 
precise conformation and orientation of the protein-bound aptamer remain ambiguous [93-95] and 
preclude any precise rationalizations on the effects conferred by the UNA on this particular aptamer. 
5. De Novo Selection of Modified Nucleic Acid Structures 
Synthetic functional nucleic acids are identified through an iterative technique known as in vitro 
selection [96-99]. The classic approach involves enriching a sequence pool for members with the 
desired activity by repeated incubation, amplification, and pool re-generation. Finally, the pool is 
sequenced. By using a pool of oligomers containing modified nucleosides it is possible to realize 
functional nucleic acid structures that natively contain these modifications. The use of such 
nucleosides in classical in vitro selection requires that they are tolerated by the enzymes used for 
amplification and regeneration of the pool [100]. To date, LNA and UNA nucleotides have only been 
used post-selection. This is probably due to the lack of the appropriate methods for maintaining LNA 
or UNA-modified pools over successive selection rounds. Phosphoramidite derivatives of all standard 
nucleobases have been introduced [6,7,101-103], thus making the initial synthesis of such libraries a 
relatively straightforward process; the lower coupling efficiencies of LNA and UNA should be taken 
into account, however, and may disfavour synthesis of sequences containing consecutive 
modifications. Reading of LNA-modified templates, as well as incorporation of triphosphates LNA 
TTP, LNA ATP, LNA GTP, and LNA 5-methyl-CTP, has been demonstrated with Taq [104], 
Vent(exo-) [104], Phusion High-Fidelity [104-106], 9° Nm [107,108], and KOD [104,109,110] DNA 
polymerases, as well as T7 RNA polymerase [107]. The most promising results published so far have 
been the successful PCR amplification of a 50-nucleotide template while incorporating LNA A at 9 
sites [109] and 21 successive incorporations of all LNA nucleosides [110]. 
Applying LNA to the classical in vitro selection setup with many rounds of selection and 
regeneration remains non-trivial (our unpublished results), and other methods might therefore be 
considered for selection of LNA-containing structures. Selection by capillary electrophoresis (CE) or 
‘non-equilibrium capillary electrophoresis of equilibrium mixtures’ (NECEEM) separates non-binding 
and binding members in solution and can yield aptamers in as few as 1-4 rounds [111-117] and may 
even alleviate the need for pool amplification [112,118]. As only a few rounds of selection are required 
with CE, the pools used rarely converge [113-116]. This is seen as an advantage though, as it indicates 
that larger sequence spaces are explored with this technique. 
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In another method the library is synthesized directly onto small beads by a split-and-mix technique 
so each bead becomes coated in a unique sequence. The library is then screened for beads that retain 
the (labelled) target, and this approach has been used for finding phosphorothioate [119] or  
iso-guanine-modified aptamers [67]. The technique is, however, limited by the very small size of the 
libraries, typically containing only a few thousand unique members.  
The enzymatic steps required for pool re-generation and sequencing can be avoided altogether by 
employing array-based selection. Microarrays have been used for assessing various mutations in a 
known aptamer [120], and this method also seems well suited for screening for activity of functional 
nucleic acids modified post-selection. More interestingly, the technique dubbed ‘closed loop aptameric 
directed evolution’ (CLADE) [121] that uses array-based libraries in combination with in silico 
evolution has been used to generate aptamers from starting pools of 5,500 [121], 46,000 [122], or 
150,000 [123] unique members. The initial array seeks to cover a large sequence space, and 
experimental binding data are then combined to mutate selected members for the next generation 
array. This approach has yielded aptamers in 4–9 selection rounds and seems suitable for even highly 
modified libraries. It therefore seems likely that the future application of LNA and UNA in functional 
acids may be based on either of these inventive approaches. 
6. Conclusions 
In conclusion, the application of LNA and UNA in functional nucleic acids is still very promising 
and definitely worth pursuing. The same goes for other LNA derivatives such as amino-LNA [124], 
which has not been covered by this review. The development of efficient protocols for enzymatic 
incorporation of modified nucleotides and reading/copying of modified oligonucleotides is reckoned 
important, specifically for selection of aptamers spiked with LNA, which are predicted to play an 
important role in diagnostics and biotechnology in the future. As summarized in this review, there are 
now numerous studies supporting the usefulness of the specific features of LNA and UNA in the field 
of RNA therapeutics, including aptamers, siRNAs, microRNAs and antagomirs, most of them working 
by hybridization as a sort of antisense oligonucleotides. In vitro selection of function nucleic acids 
with nucleoside modifications has been very successful with 2’-F pyrimidines and subsequent 
substitution with 2’-O-methylated purines. Nonetheless, LNA remains a solid candidate for post-
selection modification of stem regions and termini, where it offers nuclease resistance and can improve 
conformational stability. The presence of even a few modifications can also have a large impact on 
specificity, off-target effects, structure, stability and clearance. Even though the optimal employment 
of the novel UNA still remains to be seen, it is now largely up to companies to take advantage of both 
of these nucleoside analogues and develop them for commercial usage. 
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